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Abstract
Purpose This study investigated adherence to treatment
guidelines on cancer-related anaemia and fatigue (CRA/
CRF) and factors influencing the choice of intervention.
Methods In this prospective, observational study, 136
cancer patients being treated with chemotherapy in a large
community hospital completed a questionnaire at consec-
utive outpatient visits assessing fatigue (the Functional
Assessment of Chronic Illness Therapy—Fatigue) and
fatigue-related counselling and advice received. Data on
administration of chemotherapy and use of epoetin or blood
transfusions were abstracted from the medical records.
Results Fifty-three percent of patients with severe anaemia
(Hb<10 g/dl) and 6% of patients with less severe anaemia
(Hb levels 10–12 g/dl) received treatment (epoetin and/or
blood transfusions). Half of the patients with less severe
anaemia reported clinically relevant levels of fatigue. More
than 50% of all patients received fatigue-related counsel-
ling, primarily at the start of chemotherapy. Most counsel-
ling was directed at energy conservation. Fatigue was not
associated significantly with the use of epoetin or blood
transfusion. Patients receiving palliative treatment (17%),
male patients (16%) and patients with a low Hb level
(<6.2 g/dl, 38%) were treated significantly more often with
epoetin.
Conclusions In daily clinical practice, guidelines concerning
the use of epoetin or blood transfusion in severe CRA are
adhered to in about half of the cases. In patients with less
severe anaemia, the level of fatigue did not play a significant
role in the use of epoetin. According to current guidelines,
counselling on CRF should be directed primarily at activity
enhancement. However, only a minority of patients receive
such counselling.
Keywords Fatigue.Guidelines.Anaemia.Counselling.
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Introduction
Fatigue is a very common symptom among patients with
cancer [1]. When persistent, fatigue can seriously inhibit
patients’ ability to participate fully in the roles and activities
that make life meaningful [2, 3]. Cancer-related fatigue is
defined by the NCCN as a distressing persistent, subjective
sense of physical, emotional and/or cognitive tiredness or
exhaustion related to cancer or cancer treatment that is not
proportional to recent activity and interferes with usual
functioning [1].
The aetiology of cancer-related fatigue (CRF) is multi-
factorial and its treatment multimodal, including medical,
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DOI 10.1007/s00520-010-0848-3behavioural and psychological interventions. Factors con-
tributing to CRF that are potentially amenable to treatment
include pain, emotional distress, sleep disturbance, nutri-
tion, activity level, comorbidity and anaemia [1]. Fatigue is
associated with a diminished quality of life [3] and may be
treated with counselling as well as pharmacological
interventions, when applicable.
Counselling approaches to the treatment of CRF include
education, counselling and behavioural interventions on
activity enhancement, nutrition and sleep [1, 4]. Similar
interventions are recommended in the Dutch guidelines on
counselling for CRF [5]. Of these interventions during
active cancer treatment, activity enhancement has been
shown to result in a reduction in fatigue levels of 40–50%
[6, 7].
However, when CRF is caused by cancer-related anaemia
(CRA), pharmalogical interventions are indicated. The most
widely investigated pharmacological intervention is the
administration of epoetin. In 2002, the American Society of
Clinical Oncology (ASCO) and the American Society of
Hematology (ASH) developed an evidence-based clinical
practice guideline for the use of epoetin in patients with
cancer [8]. The guideline was updated in 2007 [9]. The use
of epoetin is recommended as an option for patients with
chemotherapy-associated anaemia with a haemoglobin level
of less than 10 g/dl (6.2 mmol/l). Use of epoetin for patients
with less severe anaemia (haemoglobin<12 g/dl
(<7.4 mmol/l) but not below 10 g/dl) should be determined
by clinical circumstances. In the 2007 update, substantially
reduced exercise capacity, lack of energy or limited ability
to carry out activities of daily living were included as
clinical circumstances to be taken into consideration when
deciding on the use of epoetin in patients with less severe
anaemia.
Despite the growing body of evidence on the impact of
fatigue on cancer patients’ health-related quality of life
(HRQL), it remains under-reported, under-diagnosed and
under-treated. For example, in a survey among 419 cancer
patients, 78% reported experiencing fatigue, but only 50%
discussed it with their oncologist, and only 27% received
any counselling or treatment [10]. In another study, only
14% of patients reporting moderate or severe fatigue
received treatment or counselling [11]. In a large European
survey on the pharmacological treatment of CRA, 39% of
anaemic patients received epoetin, transfusion or iron
supplement [12]. In an observational study among 15
oncologists and 36 patients, most discussions of and
counselling for fatigue were found to be very general and
imprecise [13].
To our knowledge, no study has yet investigated the
association between clinical signs and symptoms of
fatigue and its treatment in daily clinical practice. The
current—observational—study was undertaken to (1)
document treatment for CRF in daily clinical practice,
(2) determine the extent to which clinical practice
reflects current evidence-based practice guidelines for
CRF and (3) identify factors influencing choice of
treatment and counselling.
Methods
Study site and subjects
The study was conducted at the outpatient oncology clinic
of the Medical Center Alkmaar, a general community
teaching hospital located north of Amsterdam. On average,
1,700 newly diagnosed cancer patients are treated annually
in this hospital. Eighty percent of cancer patients in the
Netherlands are treated in general community hospitals
[14].
The study sample was composed of a consecutive
series of cancer patients starting chemotherapy treatment.
Patients were excluded if they lacked basic proficiency
in Dutch or were younger than 18 years of age. Eligible
patients were given verbal and written information about
the study prior to obtaining their informed consent. The
institutional review board of the hospital approved the
study.
The management of CRA and CRF was studied without
the medical and nursing staff being informed of the purpose
of the study. The nurses had been trained previously in the
use of the Dutch guidelines for counselling on cancer-
related fatigue [5] (see Table 1). These guidelines parallel
the international guidelines of the Oncology Nursing
Society [4].
Study design and procedures
This was a prospective, observational study. Patients were
asked to participate in the study before their initial
outpatient chemotherapy visit. After providing informed
consent, they were followed up during consecutive out-
patient visits, with a maximum of five visits.
Study measures
Patients’ sociodemographic and clinical characteristics
At the time of the initial outpatient visit, patients’ age
and gender were recorded, and clinical information,
including WHO performance status, tumour type, prior
surgical and/or radiotherapy treatment, chemotherapy
treatment intent (i.e. curative, (neo)adjuvant or palliative)
and chemotherapy schedule were extracted from the
medical records.
532 Support Care Cancer (2011) 19:531–538Haemoglobin level
Haemoglobin level was assessed before each chemotherapy
cycle. Patients were divided into three groups according to
their Hb level: <10 g/dl (severe anaemia), 10–12 g/dl (less
severe anaemia) and >12 g/dl (no anaemia). These three
categories reflect the ASCO guidelines on the use of
epoetin in patients with cancer.
Fatigue
Before each study visit, patients were asked to complete a
standardised fatigue questionnaire, the Functional Assess-
ment of Chronic Illness Therapy—Fatigue Scale (FACIT-F
Scale) [15], via a touch screen computer. The FACIT-F
scale is a 13-item questionnaire assessing fatigue and its
impact on daily activities and function during the previous
7-day period. A FACIT-F score of 30 is considered to be a
threshold for distinguishing between fatigued and non-
fatigued patients [16].
In this outpatient clinic, routine assessment and presen-
tation of patients’ HRQL via touch screen technology had
already been implemented, and the fatigue assessment was
embedded in that assessment procedure. However, results
of the fatigue questionnaire were not presented to either the
patients, the medical oncologist or to the oncology nurses
[17].
Treatment and counselling on fatigue
Information on blood transfusions and prescription of
epoetin was obtained from the medical records. Follow-
ing each cycle of chemotherapy, patients were asked to
report any counselling or advice that they had received
from the nursing or medical staff related to fatigue. The
fatigue-related counselling was grouped into six catego-
ries according to the Dutch guidelines (see Table 1),
including (1) general information and education, (2)
energy regulation, (3) sleep, (4) nutrition, (5) exercise
and (6) relaxation.
Statistical analysis
To evaluate the adherence to clinical practice guidelines
on CRA (i.e. the use of epoetin and blood transfusion),
patients were divided into three groups according to their
haemoglobin level: severely anaemic patients with Hb
levels <10 g/dl, less severely anaemic patients with Hb
levels between 10 and 12 g/dl and non-anaemic patients
with Hb level >12 g/dl. Adherence was established by
comparing the actual pharmacological treatment of the
three groups to the guidelines. Severely anaemic patients
were further divided into two groups based on the dura-
tion of the anaemia (during one chemotherapy cycle
only versus during more than one chemotherapy cycle).
Differences in the pharmacological treatment of patients
with long- versus short-term anaemia were tested with
Fisher’s exact test.
Logistic regression analysis was performed with epoetin
use or blood transfusion as the dependent variables and sex,
treatment intent (i.e. adjuvant/curative versus palliative),
haemoglobin level, level of fatigue and age as independent
variables.
For the analysis of counselling, multinomial logistic
regression analysis was performed, with type of counsel-
ling (energy conservation, physical activity, both types
of counselling or neither type of counselling) as the
dependent variable and age, sex, treatment intent (i.e.
adjuvant/curative versus palliative), haemoglobin level
and level of fatigue as independent variables. This
regression analysis was limited to these types of
counselling because less than 5% of patients received
counselling on sleep therapy, nutrition and/or restorative
therapy.
Table 1 The Dutch nursing guidelines on fatigue
The guideline consist of the following chapters
Diagnosis
Prognosis and proposed results
Interventions
Evaluation
All interventions are based on McCloskey and Bulechek [30]. The interventions described are in addition to general information on fatigue:
Energy regulation (balancing activities and rest to ensure that patients can perform the activities they wish to carry out)
Improving sleep (the rationale being that sleep disturbances may cause fatigue and may lead to inactivity)
Appropriate nutrition (to avoid malnutrition, weight loss and dehydration, which can cause fatigue)
Improving physical activity
Restorative therapy (e.g. reducing conflicts, stress, worries, etc., through recreation and relaxation)
Support Care Cancer (2011) 19:531–538 533Multilevel logistic regression analysis, with counselling
(yes versus no) as the dependent variable and age, sex,
treatment intent (i.e. adjuvant/curative versus palliative),
haemoglobin level and level of fatigue as independent
variables was performed to investigate the temporal pattern
of advice during the course of treatment.
Assuming a 20% to 25% difference between the
proportion of patients receiving a given treatment as a
function of Hb level, with alpha set at 5% and power at
80%, 128 patients were required [18].
Results
Patient and nurses recruitment and sample description
Between January 2006 and November 2006, 140 patients
were invited to participate in the study, of whom 136
agreed (97% response rate).
Table 2 presents the patients’ sociodemographic and
clinical characteristics. The median age of the patients was
62 years, and 62% was female. More than half of the
patients were receiving treatment for breast cancer. Approx-
imately half of the patients were receiving palliative
treatment.
Treatment for CRA
Table 3 presents results on the treatment of anaemia in
relation to patients’ Hb and fatigue levels. Twenty-six of the
136 patients (19.1%) had an Hb<10 g/dl, indicative of severe
anaemia. The ASCO guidelines recommend treating these
patients with epoetin. Blood transfusion is also a treatment
option. Fourteen (54%) of these patients actually received
treatment with epoetin and/or blood transfusion. However,
when anaemia was not related to chemotherapy, patients were
treated conforming to standard hospital procedures. These
other causes were not further investigatedin the present study.
Seventy-two patients (52.9%) had an Hb value between
10 and 12 g/dl. According to the prevailing treatment
guidelines, use of epoetin and/or blood transfusions for
patients with less severe anaemia should be determined on
the basis of clinical observation of symptoms. Of these 72
patients, only four (5.5%) received epoetin and/or a blood
transfusion. However, half of these 72 patients with less
severe anaemia reported clinically relevant levels of fatigue
(i.e. FACIT-F scores of 30 or less).
Finally, 38 patients (27.9%) had Hb levels above 12 g/dl.
None of these patients received treatment with epoetin,
which is in accordance with the guidelines. However, one
patient received a blood transfusion.
Table 3 Pharmacological interventions for fatigue in relation to haemoglobin level as defined by the ASCO guidelines and level of fatigue
Pharmacological intervention Hb<10 g/dl
a n=26 Hb 10–12 g/dl n=72 Hb>12 g/dl n=38
n FACIT-F<30
b n=36 FACIT-F>30 n=36 n
nn
Epoetin 6 1 1 0
Blood transfusion 5 0 1 1
Epoetin and blood transfusion 3 0 1 0
No treatment 12 35 33 37
aHb levels corresponding to ASCO guidelines on use of epoetin
bA score of 30 on the FACIT-F scale is the threshold for distinguishing between fatigued and non-fatigued patients
Table 2 Patient characteristics
n (%)
Gender Female 84 (61.8)
Male 52 (38.2)
Age (range) 62 (40–87)
Type of chemotherapy Curative/adjuvant 57 (41.9)
Palliative 69 (50.7)
Neo-adjuvant 10 (7.4)
Radiotherapy 39 (28.7)
Before chemotherapy 19 (48.7)
During chemotherapy 18 (46.2)
After chemotherapy 2 (5.1)
Surgery 63 (46.3)
Primary cancer Breast 52 (38.2)
Lung 29 (21.3)
Colorectal 33 (24.3)
Urogenital 4 (2.9)
Gynaecological 5 (3.7)
Lymphoma 8 (5.8)
Other 5 (3.7)
Number of chemotherapy
cycles
1 14 (10.3)
2 13 (9.6)
3 9 (6.6)
4 22 (16.2)
5 or more 78 (57.4)
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duration of anaemia and treatment. Nineteen of the 26
severely anaemic patients experienced an Hb of <10 g/dl on
only one occasion, of whom 11 (58%) received treatment
(epoetin and/or blood transfusion). Seven of the 26 severely
anaemic patients experienced an Hb<10 g/dl during more
than one treatment cycle, of whom three (43%) received
treatment. Thus, the duration of the anaemia was not a
significant factor in the decision to use epoetin or blood
transfusions (p=0.67).
Table 5 presents the results of the analysis of predictors
of pharmacological treatment. Seventeen percent of the
patients receiving palliative treatment versus 2% of those
receiving adjuvant/curative treatment were treated with
epoetin (p=0.01, OR=45.8). Sixteen percent of the male
patients versus 5% of the female patients were treated with
epoetin (p=0.03, OR=0.09). As expected, significantly
more patients with a lower Hb level (38%) were treated
with epoetin (p<0.001, OR=0.07) and blood transfusions
(p=0.001, OR=0.14) than patients with a higher Hb level
(3%; p<0.001). Level of fatigue was not associated
significantly with the use of epoetin or blood transfusion.
Counselling for fatigue
Table 6 presents the results pertaining to counselling for
cancer-related fatigue. Sixty-three percent of patients
received counselling for CRF. More than half of the
patients (n=75; 55%) received counselling on energy
conservation, 24 patients (18%) received counselling on
physical activity and less than 5% of patients received
counselling on sleep therapy, nutrition and/or restorative
therapy. Multinomial logistic regression analyses indicated
that patients with a higher FACIT-F score (i.e. less fatigued)
were more likely to receive counselling on energy con-
servation (p= 0 . 0 0 2 ,O R1 . 0 7 ) .H bl e v e l ,a g e ,t r e a t m e n t
intent and sex were not associated significantly with the
type of counselling.
Approximately half of the patients received counselling
on CRF during the first cycle of chemotherapy. Across
Table 4 Pharmacological interventions for patients with a Hb level <10 g/dl during one versus more than one chemotherapy cycle
Pharmacological treatment (epoetin and/or blood transfusion) Hb level <10 g/dl during more than one chemotherapy treatment cycle
Yes (n=7) No (n=19)
Yes (n=14) 3 11
No (n=12) 4 8
p=0.67 (Fisher exact test)
Table 5 Logistic regression analysis on the use of epoetin and/or blood transfusion
% Patients
receiving epoetin
OR CI p
value
a
% Patients receiving blood
transfusion
OR CI p
value
a
Age <60 (n=61) 11 0.9 0.9–1.0 0.2 3 1.0 1.0–1.1 0.4
>60 (n=70) 7 13
Sex Male
(n=50)
16 0.09 0.01–0.82 0.03 16 0.23 0.04–1.2 0.09
Female
(n=81)
54
Treatment
intent
Adjuvant/
curative
(n=66)
2 45.8 2.3–910 0.01 6 0.55 0.1–3.2 0.5
Palliative
(n=65)
17 11
Hb level
b <10 g/dl
(n=24)
38 0.07 0.02–0.3 <0.001 33 0.14 0.04–0.4 0.001
>10 g/dl
(n=107)
33
FACIT-F
b <30 (n=67) 6 1.1 1.0–1.2 0.06 9 1.0 0.9–1.1 0.9
>30 (n=64) 13 8
ap value based on logistic regression analysis with the binary variables sex and treatment intent and the continuous variables age, Hb level and FACIT-F as
independent variables
bLowest level during all treatment courses
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level logistic regression analysis confirmed that patients
were counselled significantly more often at the beginning
of the treatment (p<0.05), as compared to during other
treatment cycles. This was not influenced by patient or
treatment characteristics, including Hb levels (data not
shown).
Discussion
In this observational study, we found that only 53% of
patients with severe CRA (Hb<10 g/dl) and 6% of patients
with less severe CRA (Hb levels 10–12 g/dl) received
treatment with epoetin and/or blood transfusions. In
addition, approximately 50% of patients with less severe
anaemia experienced fatigue and thus, according to current
practice guidelines, should have been considered for treat-
ment. More than 50% of the patients received specific
fatigue-related counselling. Most counselling was directed
at energy conservation.
In 2002 and 2007, the ASCO and the ASH published
evidence-based guidelines on the use of epoetin and blood
transfusion in patients with cancer [8, 9]. In our study, only
a minority of patients actually received treatment with
epoetin, although approximately half of the patients could
have been considered for such treatment based on their Hb
level alone or in combination with their self-reported
fatigue levels. While the ASCO guidelines mention the
relevance of clinical circumstances in determining the
appropriateness of medical intervention for fatigue, they
do not provide explicit criteria in this regard. The European
Cancer Anaemia Survey (ECAS) of more than 15,000
cancer patients found that more than 60% of anaemic
patients are not treated with epoetin [12].
In our study, several factors may have played a role in
the limited adherence to guidelines on the use of epoetin.
First, safety issues may have influenced treatment deci-
sions. Several recent studies have reported that the use of
epoetin in cancer patients can have a negative impact on
survival [19–21]. These findings triggered a review by the
US Food and Drug Administration (FDA) Oncologic Drugs
Advisory Committee and resulted in the FDA updating the
product labelling of epoetin. It should be noted, however,
that the risks for higher mortality and/or shortened time to
tumour progression were demonstrated in studies where
epoetins were dosed with the intent to achieve Hb values
greater than or equal to 12 g/dl [22]. The risk of shortened
survival and tumour progression have not been demon-
strated when epoetins are dosed to reach a haemoglobin
value of <12 g/dl. Nevertheless, the place of epoetin in the
treatment of CRA and CRF remains the subject of
continueddiscussion, particularlyinpatientswith advanced
cancer receiving palliative care [23].
A second factor possibly related to the limited use of
epoetins is the failure of health care providers to recognise
clinically relevant levels of fatigue. Again, although
practice guidelines indicate that clinical circumstances
should contribute to decisions regarding the use of epoetin
or blood transfusions, no specific guidance is provided as to
how such clinical circumstances, including assessment of
fatigue, should be documented. Other studies have also
failed to observe a significant association between the use
of blood transfusions and patients’ fatigue levels [10, 11,
13, 24].
Regarding counselling for CRF, previous studies have
reported that between 14% and 27% of cancer patients
receive treatment or advice about the management of their
fatigue [10, 25]. The relatively high percentage of patients
in our study (more than 50%) reporting having received
specific counselling on fatigue is notable. However, we
found that most of the fatigue-related counselling was
directed towards energy conservation, rather than enhance-
ment of physical activity levels. Previous studies have also
reported that fatigued patients are most commonly advised
to rest and relax [10]. More recent studies suggest,
Table 6 Number of patients receiving counselling on cancer-related fatigue as a function of self-reported fatigue levels
Counselling FACIT-F<30
a FACIT-F>30 p value Total
(n=35) (n=101) (n=136)
n (%) n (%) n (%)
Energy conservation 9 (26) 66 (65) <0.01
b 75 (55)
Sleep 0 (0) 4 (4) 0.57
c 4 (3)
Nutrition 1 (3) 1 (1) 0.45
c 2 (2)
Physical activity 6 (17) 18 (18) 0.93
b 24 (18)
Restorative therapy 0 (0) 0 (0) – 0 (0)
aScore at first visit, a score of 30 on the FACIT-F scale is the threshold for distinguishing between fatigued and non-fatigued patients
bChi-square statistic
cFisher’s exact test
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powerful, positive effect on fatigue. Conversely, reducing
physical activity levels may lead to reduced levels of
physical fitness and thus may exacerbate fatigue symptoms
[6, 7]. For this reason, the current guidelines recommend
efforts to increase levels of physical activity.
We would note that the nurses in our study were aware
of the guidelines on counselling for fatigue and had, in fact,
undergone continuing education in this area. However, this
was apparently not sufficient to bring about a shift from
r e c o m m e n d i n ge n e r g yc o n s e r v a t i o nt or e c o m m e n d i n g
activity enhancement. The seemingly counterintuitive find-
ing that a greater percentage of patients without fatigue
reported having been counselled on energy conservation
may reflect a tendency by the nurses to counsel non-
fatigued patients not to overexert themselves.
Several possible limitations of this study should be noted.
First, patient self-report data were used to evaluate the
counselling that patients’ received. Ideally, evaluation of
health care communication at the individual level is carried
out using audiotapes or videotapes. This was not feasible in
the current study due to both technical and privacy reasons.
Although self-report data have their limitations, our previous
study found that information provided by oncology patients
about what was discussed during outpatient chemotherapy
visits is quite accurate (when compared to information
provided by observers) [26].
Second, despite the fact that this study is one of the
largest of its kind, the sample size limited the statistical
power available for some of the subgroup analyses. For
example, with a larger sample, the marginal association
observed between the use of epoetin and self-reported
fatigue levels might have been more clearly significant.
Conclusions
Guidelines regarding medical treatment options for CRA or
CRF are reasonably precise. Nevertheless, there is a
reluctance to prescribe pharmacological treatments, even
when they are recommended by published treatment
guidelines. A variety of adherence barriers have been
suggested in earlier studies, including the lack of awareness
of the guidelines, disagreement with them, scepticism about
the effectiveness of guideline-driven management, in
general, lack of confidence in the ability to implement
guidelines and inertia [27]. Given more recent findings
regarding the potential dangers associated with the use of
epoetins, some of this reluctance may be justified.
The guidelines on counselling for CRF could benefit
from further clarification. First, they need to be reformu-
lated into best practices, with the most successful counsel-
ling strategies being highlighted. In particular, the positive
effects of activity enhancement need to be emphasised.
Additionally, ongoing, repeated counselling may enhance
its effectiveness, as has been shown in other patient
populations [28]. Additionally, tailored counselling that
takes clinical (e.g. stage of disease) and patient (age and
gender) characteristics into consideration may further
optimise its effectiveness.
Finally, the value of the guidelines on the treatment
of CRA and CRF might be enhanced by explicitly
recommending the use of self-reported measures to monitor
fatigue in daily clinical practice. Integrating the assessment
of commonly experienced symptoms such as fatigue into
daily clinical practice may have important implications
for improving symptom management [29]. Ideally, use of
clinically relevant thresholds for patient-reported fatigue
could be tied to appropriate clinical pathways for the
treatment of CRA and CRF. Any future enhancements in
counselling for CRF should be investigated empirically,
preferably in the context of a randomised clinical trial,
in order to establish a strong evidence base for such
interventions.
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